Spyre Therapeutics, Inc. (SYRE) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "AGLE",
        "SYRE"
      ],
      "issuer_cik": "0001636282",
      "owner_cik": "0001853327",
      "accession_number": "0001636282-26-000117",
      "form_type": "4",
      "filing_date": "2026-10-02",
      "period_of_report": "2026-09-30",
      "issuer_name": "Spyre Therapeutics, Inc.",
      "issuer_trading_symbol": "SYRE",
      "owner_name": "Burrows Scott L",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Financial Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-01",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 3071,
      "transaction_price_per_share": 92.95,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 79991,
      "transaction_value": 285449.45,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F2",
          "description": "This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."
        },
        {
          "id": "F6",
          "description": "The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.54 to $93.53, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."
        }
      ]
    },
    {
      "tickers": [
        "AGLE",
        "SYRE"
      ],
      "issuer_cik": "0001636282",
      "owner_cik": "0001758363",
      "accession_number": "0001636282-26-000118",
      "form_type": "4",
      "filing_date": "2026-10-02",
      "period_of_report": "2026-10-01",
      "issuer_name": "Spyre Therapeutics, Inc.",
      "issuer_trading_symbol": "SYRE",
      "owner_name": "Turtle Cameron",
      "is_director": true,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Executive Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-10-01",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 600,
      "transaction_price_per_share": 89.14,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 551940,
      "transaction_value": 53484,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."
        },
        {
          "id": "F2",
          "description": "The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.52, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."
        },
        {
          "id": "F3",
          "description": "Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.